CLINICAL TRIALS PROFILE FOR GELNIQUE 3%
✉ Email this page to a colleague
All Clinical Trials for gelnique 3%
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01192568 ↗ | Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder | Recruiting | Allergan | Phase 4 | 2011-05-02 | This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition. Children will be treated with 0.75 g of gel/day for two weeks. Patients will then return to the clinic for a potential dose titration. At this time their dose may be adjusted up to 1g/day, down to 0.5g/day, or remain the same at 0.75g of gel/day depending on the individual response and tolerability. The total treatment time is 14 weeks and total time on the study is 16 weeks. |
| NCT01192568 ↗ | Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder | Recruiting | Watson Pharmaceuticals | Phase 4 | 2011-05-02 | This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition. Children will be treated with 0.75 g of gel/day for two weeks. Patients will then return to the clinic for a potential dose titration. At this time their dose may be adjusted up to 1g/day, down to 0.5g/day, or remain the same at 0.75g of gel/day depending on the individual response and tolerability. The total treatment time is 14 weeks and total time on the study is 16 weeks. |
| NCT02386072 ↗ | A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) | Completed | Astellas Scientific & Medical Affairs, Inc. | 2015-01-05 | A study to identify factors that are associated with improved effectiveness in pharmacologic therapy of Overactive Bladder, from the patient perspective primarily measured by OAB-Q-SF (Overactive Bladder Questionnaire Short Form) | |
| NCT02633371 ↗ | A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults | Completed | Society for Pediatric Dermatology | N/A | 2016-02-01 | This is a single-center, prospective, open-label, outpatient pilot study evaluating the efficacy and tolerability of oxybutynin gel for axillary hyperhidrosis. |
| NCT02633371 ↗ | A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults | Completed | University of Colorado, Denver | N/A | 2016-02-01 | This is a single-center, prospective, open-label, outpatient pilot study evaluating the efficacy and tolerability of oxybutynin gel for axillary hyperhidrosis. |
| NCT02961790 ↗ | Oxybutynin Chloride in Managing Hot Flashes | Completed | National Cancer Institute (NCI) | Phase 3 | 2016-12-09 | This randomized phase III trial studies how well oxybutynin chloride works in managing hot flashes in patients who are not candidates for, or not interested in hormone replacement therapy. Previous studies have shown that oxybutynin is effective in managing hot flashes, however doses used in prior studies have resulted in side effects. This trial is evaluating lower doses of oxybutynin with the goal of determining if they are efficacious with less side effects. ADAM-VTE |
| NCT02961790 ↗ | Oxybutynin Chloride in Managing Hot Flashes | Completed | Academic and Community Cancer Research United | Phase 3 | 2016-12-09 | This randomized phase III trial studies how well oxybutynin chloride works in managing hot flashes in patients who are not candidates for, or not interested in hormone replacement therapy. Previous studies have shown that oxybutynin is effective in managing hot flashes, however doses used in prior studies have resulted in side effects. This trial is evaluating lower doses of oxybutynin with the goal of determining if they are efficacious with less side effects. ADAM-VTE |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for gelnique 3%
Condition Name
Clinical Trial Locations for gelnique 3%
Trials by Country
Clinical Trial Progress for gelnique 3%
Clinical Trial Phase
Clinical Trial Sponsors for gelnique 3%
Sponsor Name
